Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens

N P Juffermans; A Verbon; M J Schultz; C E Hack; S J van Deventer; P Speelman; T van der Poll

doi:10.1128/AAC.45.5.1547-1549.2001

Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens

Antimicrob Agents Chemother. 2001 May;45(5):1547-9. doi: 10.1128/AAC.45.5.1547-1549.2001.

Authors

N P Juffermans¹, A Verbon, M J Schultz, C E Hack, S J van Deventer, P Speelman, T van der Poll

Affiliation

¹ Laboratory of Experimental Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Abstract

Ingestion of thalidomide was associated with a reduction in the upregulation of the granulocyte activation marker CD11b and a reduced capacity to release elastase and lactoferrin after stimulation with lipopolysaccharide or lipoteichoic acid. A single oral dose of thalidomide attenuates neutrophil activation upon ex vivo stimulation with bacterial antigens.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Inflammatory Agents / pharmacology*
Antigens, Bacterial / pharmacology*
Drug Interactions
Granulocytes / drug effects*
Granulocytes / metabolism
Humans
Lactoferrin / metabolism
Lipopolysaccharides / pharmacology
Macrophage-1 Antigen / metabolism*
Neutrophil Activation / drug effects*
Pancreatic Elastase / metabolism
Thalidomide / pharmacology*

Substances

Anti-Inflammatory Agents
Antigens, Bacterial
Lipopolysaccharides
Macrophage-1 Antigen
Thalidomide
Lactoferrin
Pancreatic Elastase